Clinical drug trials in Irkutsk Scientific Center of Surgery and Traumatology began in 2005. In 2013, the laboratory of clinical trials was established in the science department of clinical surgery. We analyzed the experience of Irkutsk Scientific Center of Surgery and Traumatology in international multicentre trials. Participation in international mul-ticentre trials allows the Irkutsk Scientific Center of Surgery and Traumatology to get affiliated with the publications in first quartile scientific journals. The experience of the laboratory in clinical trials is projected into practical work of other institutes – Hospital of Irkutsk Scientific Center SB RAS and Irkutsk Regional Clinical Hospital. The important objectives of the laboratory of clinical trials are developing the protocols, performing drug clinical trials and medical device clinical trials. The laboratory carries out admission of patients for observational trial PROTOCOL. One of the fields of work of the laboratory is the prospect of clinical testing of developed clinical technologies.
international multicentre trial, drug clinical trials, laboratory of clinical trials, clinical testing, observational trial
1. ZelenskayaEM, SubbotovskayaAI, GanyukovVI, KocherginNA, BarbarichVB, SarayevaNO, Vybi-vantsevaAV, ApartsinKA, LifshitsGI (2015). “PROTOCOL” trial: preliminary results of the project [Issledovanie «PROTOKOL»: predvaritel’nye rezul’taty v ramkakh proekta]. Rossiyskiy kardiologicheskiy zhurnal, (10), 75-80
2. LifshitsGI, ApartsinKA (2015). Prospective, mul-ticenter observational study PROTOCOL: Personalized therapy with Clopidogrel after stenting at acute coro-nary syndrome with account of genetic polymorphisms [Prospektivnoe mnogotsentrovoe nablyudatel’noe issledovanie PROTOKOL: Personalizirovannaya terapiya klopidogrelom pri stentirovanii po povodu ostrogo koronarnogo sindroma s uchetom geneticheskikh polimorfizmov]. Kachestvennaya klinicheskaya praktika, (1), 78-86.
3. LifshitsGI, KokhNV, ApartsinKA (2015). Develop-ment of portable device for multiparameter monitor-ing of antithrombotic therapy with account of genetic polymorphisms [Sozdanie portativnogo pribora dlya mul’tiparametricheskogo kontrolya antitromboticheskoy terapii s uchetom geneticheskikh polimorfizmov]. Person -alizirovannaya meditsina i global’noe zdorov’e: Materialy mezhdunarodnoy konferentsii (Astana, Kazakhstan, 13-14 maya 2015 g.), 59-60.
4. Good Clinical Practice: National Standard of the Rus-sian Federation [Nadlezhashchaya klinicheskaya praktika: Natsional’nyy standart Rossiyskoy Federatsii]. Available at: http://acto-russia.org/index.php?option=com_con-tent&;task=view&id=17 (Accessed May 19, 2016)
5. Concerning approval of the Regulation on organi-zation of clinical testing of the methods of prevention,diagnostics, treatment and rehabilitation and the de-livery of health care in the course of clinical testing of the methods of prevention, diagnostics, treatment and rehabilitation (including procedure of referral of the patients to the health care), standard form of clinical testing of the methods of prevention, diagnostics, treat-ment and rehabilitation: Order of the Ministry of Health of the Russian Federation d.d. July 10, 2016 N433n [Ob utverzhdenii Polozheniya ob organizatsii klinicheskoy aprobatsii metodov profilaktiki, diagnostiki, lecheniya i reabilitatsii i okazaniya meditsinskoy pomoshchi v ramkakh klinicheskoy aprobatsii metodov profilaktiki, di-agnostiki, lecheniya i reabilitatsii (v tom chisle poryadka napravleniya patsientov dlya okazaniya takoy meditsin-skoy pomoshchi), tipovoy formy protokola klinicheskoy aprobatsii metodov profilaktiki, diagnostiki, lecheniya i reabilitatsii: Prikaz Ministerstva zdravookhraneniya RF ot 10.07.2015 g. No433n]. Available at: https://www.rosminzdrav.ru/documents/9211-prikaz-ministerst-va-zdravoohraneniya-rf-ot-10-iyulya-2015-g-433n-ob-utverzhdenii-polozheniya-ob-organizatsii-kliniches-koy-aprobatsii-metodov-profilaktiki-diagnostiki-lech-eniya-i-reabilitatsii-i-okazaniya-meditsinsko (Accessed May 19, 2016).
6. Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV (2016). Available at: https://clinicaltrials.gov/ct2/show/study/NCT00596752?term=ESPECIAL&;rank=2§=X01256 (Accessed May 19, 2016).
7. DecoususH, PrandoniP, MismettiP, BauersachsR, BodZ, BrennerB, LaporteS, MatyasL, MiddeldorpS, SokurenkoG, LeizoroviczA (2010). Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N. Engl. J. Med., 363(13), 1222-1232.
8. DecoususH, PrandoniP, MismettiP, BauersachsR, BodZ, BrennerB, LaporteS, MatyasL, MiddeldorpS, SokurenkoG, LeizoroviczA (2013). Edoxaban versus Warfarin for the treatment of symptomatic venous throm-boembolism. N. Engl. J. Med., 369(15), 1406-1415.
9. KalliomäkiJ, AttalN, JonzonB, BachF, HuizarK, RatcliffeS, ErikssonB, JaneckiM, DanilovA, BouhassiraD (2013). A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in post-traumatic neuralgia. Pain, 154(5),761-767.
10. O’DonoghueM, GlaserR, CavenderM, AylwardP, BonacaM, BudajA, DaviesR, DellborgM, FoxK, GutierrezJ, HammC, KissR, KovarF, KuderJ, ImK, LeporeJ, Lopez-SendonJ, OphuisT, ParkhomenkoA, ShannonJ, SpinarJ, TanguayJ, RudaM, StegP, TherouxP, WiviottS, LawsI, SabatineM, MorrowD (2016). Effect of Losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial. JAMA, 315(15), 1591.
11. PrandoniP, CasigliaE, TikhonoffV, Leizo-roviczA, DecoususH (2011). The risk of subsequent cancer and arterial cardiovascular events in patients with superficial vein thrombosis in the legs. Blood, 118(17), 4719-4722.
12. SamamaC, LecoulesN, KierzekG, ClaessensY, RiouB, RosencherN, MismettiP, SautetA, BarrellierM, ApartsinK, JonasM, CaeiroJ, van der VeenA, RoyP (2013). Comparison of fondaparinux with low-molec-ular-weight heparin for VTE prevention in patients requiring rigid or semi-rigid immobilization for isolated non-surgical below-knee injury. J. Thromb. Haemost, 11(10), 1833-1843.
13. VybivantsevaAV , DemkovaOV, KoryakinaLB, AndreevaEO, SaraevaN O, LifshitsG I, ApartsinKA (2015). Impact of preanalytical delay on results of light trans-mittance aggregometry in STEMI patients. J. Thromb. Haemost, 13 (Suppl.2), 283.
